Docetaxel (Taxotere®) has been one of the most important chemotherapeutic drugs for
cancer treatment since 1996. Although a large number of clinical studies have been …

The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Introduction Data on immuno-oncology agents in Chinese patients are limited despite a
need for new therapies. We evaluated the efficacy and safety of nivolumab in a …

Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …

According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …

Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon,
pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase …

Lung cancers with a mutated epidermal growth factor receptor (EGFR) are a major
contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been …